Biomerieux SA operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biomerieux SA with three other
pharmaceutical manufacturers in Europe:
H. Lundbeck A/S
sales of 17.67 billion Danish Kroner [US$2.77 billion]
of which 100%
Stada Arzneimittel AG
(3.01 billion Euros [US$3.50 billion]
of which 55%
was Generics), and
(2.69 billion Euros [US$3.13 billion]
of which 89%
was Specialty Care).
During the third
quarter of 2021, sales at Biomerieux SA totalled
877.40 million Euro.
an increase of 11.1%
from the 789.40 million Euro in sales at the company during the third quarter of 2020.
During the first three quarters of 2021, sales totalled 2.45 billion Euro, which is
than through the first three
quarters of 2020.
During the previous 34 quarters, sales at Biomerieux SA have increased compared with the same quarter in the previous year.
Sales at Biomerieux SA appear to have some seasonality: during each of the previous 9
years, sales have been highest during the fourth quarter, which has accounted for
between 26.8% and 29.8%
of the annual
Biomerieux SA reported sales of 3.12 billion Euro (US$3.63 billion)
December of 2020.
increase of 16.6%
versus 2019, when the company's sales were 2.67 billion Euro.
Sales at Biomerieux SA have increased during each of the previous five years
(and since 2015, sales have increased a total of 59%).
Sales of Diagnostic Clinical Equipment saw an increase
20.6% in 2020, from
2.21 billion Euro to 2.66 billion Euro.
Not all segments of Biomerieux SA experienced an increase in sales in 2020:
sales of Microbiological Industrial Equipment fell 2.6% to 454.60 million Euro.